Home
About
Overview
Sharing Data
ORCID
Help
History (1)
The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease.
The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease. Aliment Pharmacol Ther. 2017 07; 46(2):162-168.
View in:
PubMed
subject areas
Adult
Biological Products
Colitis, Ulcerative
Crohn Disease
Disease Progression
Drug Therapy, Combination
Female
Gastrointestinal Agents
Humans
Inflammatory Bowel Diseases
Infliximab
Male
Middle Aged
Phenotype
Prospective Studies
Time Factors
Tumor Necrosis Factor-alpha
authors with profiles
Joel R. Pekow